Using decision analysis to compare policies for antenatal screening for Down's syndrome

Abstract Objective : To compare different screening policies for Down's syndrome across a broad range of outcomes, using decision analysis, with particular reference to the role of maternal serum testing. Design : A decision tree was used to combine data from local sources and the medical literature to predict the likely frequency of several outcomes. Sensitivity analyses were used to test the robustness of the conclusions drawn. Setting : Oxfordshire Health Authority. Main outcome measures : Live births with and without Down's syndrome; miscarriages with Down's syndrome; cases of Down's syndrome detected antenatally; amniocenteses performed (and associated miscarriages); direct NHS screening costs; number of women offered screening. Results : Screening policies for Down's syndrome that include serum testing can produce better population outcomes than programmes that do not. Each option for screening for Down's syndrome that we considered had significant drawbacks. In Oxfordshire, offering serum testing to women of all ages would prevent the birth of approximately one more baby with Down's syndrome per year than would a policy of screening for women aged 30 years or more. The cost of preventing this one extra Down's birth would be one or two normal babies lost after amniocentesis, 4500 blood tests for young women (with the associated anxiety and counselling), approximately 200 false positive serum test results and amniocenteses (with the associated anxiety and distress), and £90000 for the extra tests, counselling, and amniocenteses. Opinions are divided as to which policy is the better option for the population. Conclusions : Decision analysis is a useful tool for determining the likely consequences of different policy options across a broad range of outcomes. This focuses debate and decision making on outcomes of care, which in turn makes it clear that the choice of screening programme for Down's syndrome depends on the relative importance ascribed to the different outcomes. If individuals' values vary widely it may be impossible to find one screening policy that meets the needs of all pregnant women.

[1]  Gordon H. Guyatt,et al.  Users' Guides to the Medical Literature: I. How to Get Started , 1993 .

[2]  R. Slotnick,et al.  Sensitivity and Specificity of Screening for Down Syndrome With Alpha‐Fetoprotein, hCG, Unconjugated Estriol, and Maternal Age , 1991, Obstetrics and gynecology.

[3]  T. Marteau,et al.  Presenting a routine screening test in antenatal care: practice observed. , 1992, Public health.

[4]  M. Piggott,et al.  Serum screening for Down's syndrome. , 1995, Midwives : official journal of the Royal College of Midwives.

[5]  K. Spencer,et al.  Free Beta Human Choriogonadotropin in Down's Syndrome Screening: A Multicentre Study of its Role Compared with other Biochemical Markers , 1992, Annals of clinical biochemistry.

[6]  P. Riley,et al.  Prenatal screening for Down's syndrome. , 1991, BMJ.

[7]  J. Simpson,et al.  Maternal Serum Screening for Fetal Down Syndrome in Women Less Than 35 Years of Age Using Alpha-Fetoprotein, hCG, and Unconjugated Estriol: A Prospective 2-Year Study , 1992, Obstetrics and gynecology.

[8]  J. Green,et al.  Serum screening for Down's syndrome: some women's experiences. , 1993, BMJ.

[9]  T. Marteau.  Psychological consequences of screening for Down's syndrome. , 1993, BMJ.

[10]  I. McFadyen,et al.  Screening for Down's syndrome. , 1988, BMJ.

[11]  C. Harman,et al.  Intravenous fetal transfusion of immunoglobulin for alloimmune thrombocytopenia , 1992, The Lancet.

[12]  Ann Tabor,et al.  RANDOMISED CONTROLLED TRIAL OF GENETIC AMNIOCENTESIS IN 4606 LOW-RISK WOMEN , 1986, The Lancet.

[13]  Prenatal screening for Down's syndrome with use of maternal serum markers. , 1993, The New England journal of medicine.

[14]  G. Guyatt,et al.  Users' guides to the medical literature. , 1993, JAMA.

[15]  A. Mcguire,et al.  Antenatal screening for Down's syndrome. , 1992, Journal of medical screening.

[16]  Eui Jung.  Prenatal screening for Down's syndrome. , 2010, BMJ.

[17]  A. Dawson,et al.  Serum screening for Down's syndrome , 1993, British journal of obstetrics and gynaecology.

[18]  T. Sheldon,et al.  Appraisal of a new scheme for prenatal screening for Down's syndrome. , 1991, BMJ.

[19]  J P Kassirer,et al.  Incorporating patients' preferences into medical decisions. , 1994, The New England journal of medicine.

[20]  N. Wald,et al.  The extent of Down's syndrome screening in Britain in 1991 , 1992, The Lancet.

[21]  F. Dunstan,et al.  Age‐Specific Detection and False‐Positive Rates: An Aid to Counseling in Down Syndrome Risk Screening , 1993, Obstetrics and gynecology.

[22]  Royal College of Obstetricians and Gynaecologists , 1948 .

[23]  P. Shackley,et al.  An economic appraisal of alternative pre-natal screening programmes for Down's syndrome. , 1993, Journal of public health medicine.

[24]  R. Lilford,et al.  Decision analysis in medicine. , 1992, BMJ.

[25]  N. Wald,et al.  Antenatal maternal serum screening for Down's syndrome: results of a demonstration project. , 1992, BMJ.